AR036354A1 - Preparacion solida - Google Patents

Preparacion solida

Info

Publication number
AR036354A1
AR036354A1 ARP020103187A ARP020103187A AR036354A1 AR 036354 A1 AR036354 A1 AR 036354A1 AR P020103187 A ARP020103187 A AR P020103187A AR P020103187 A ARP020103187 A AR P020103187A AR 036354 A1 AR036354 A1 AR 036354A1
Authority
AR
Argentina
Prior art keywords
group
magnesium
optionally substituted
aluminum hydroxide
coprecipitate
Prior art date
Application number
ARP020103187A
Other languages
English (en)
Inventor
M Sugaya
T Shimizu
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR036354A1 publication Critical patent/AR036354A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una preparación sólida desintegrable gástrica que comprende un ingrediente activo inactivador del ácido de acción antiulcerosa y neutralizante rápido del ácido estomacal que suprime la generación de anhídrido carbónico permitiendo el efecto farmacológico del ingrediente activo, y por lo menos un componente seleccionado de los óxidos de metal e hidróxidos de metal, cuyo tiempo de desintegración preferentemente está dentro de los 7 minutos. Además, dicha preparación no posee capa entérica. La preparación comprende adicionalmente por lo menos un componente seleccionado de los carbonatos de metal alcalino y térreo y los aditivos básicos que poseen una elevada solubilidad en agua. El ingrediente activo inactivador del ácido es un compuesto representado por la fórmula (1) en donde el anillo A es un anillo de benceno opcionalmente sustituido, R1 es átomo de hidrógeno, un grupo aralquilo opcionalmente sustituido, grupo acilo o grupo aciloxilo, R2, R3 y R4 son iguales o diferentes y cada uno representa un átomo de hidrógeno, un grupo alquilo opcionalmente sustituido, un grupo alcoxilo opcionalmente sustituido o un grupo amino opcionalmente sustituido, e Y representa un átomo de nitrógeno o CH, o una sal del mismo. El óxido de metal se selecciona del grupo que consiste en óxido de magnesio, silicato de magnesio, gel de hidróxido de aluminio seca y aluminato de metasilicato de magnesio y el hidróxido de metal se selecciona del grupo que consiste en hidrato de magnesio, hidróxido de aluminio, hidrotalcita sintética, coprecipitado de hidróxido de aluminio e hidróxido de magnesio, coprecipitado de hidróxido de aluminio, carbonato de magnesio y carbonato de calcio, y coprecipitado de hidróxido de aluminio y bicarbonato de sodio.
ARP020103187A 2001-08-31 2002-08-26 Preparacion solida AR036354A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001263481 2001-08-31
JP2001341477 2001-11-07
JP2002060006 2002-03-06

Publications (1)

Publication Number Publication Date
AR036354A1 true AR036354A1 (es) 2004-09-01

Family

ID=27347410

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103187A AR036354A1 (es) 2001-08-31 2002-08-26 Preparacion solida

Country Status (6)

Country Link
US (1) US20040248939A1 (es)
EP (1) EP1420763A1 (es)
AR (1) AR036354A1 (es)
CA (1) CA2448760A1 (es)
PE (1) PE20030436A1 (es)
WO (1) WO2003017980A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
EA006398B1 (ru) 2001-06-01 2005-12-29 Поузен Инк. Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2283172B1 (es) * 2005-01-21 2008-08-16 Universidad De Granada Suspension extemporanea de omeprazol para via oral.
EP1901719A2 (en) * 2005-07-11 2008-03-26 Nycomed Danmark ApS Benzimidazole formulation
US20070020334A1 (en) * 2005-07-11 2007-01-25 Poul Bertelsen Benzimidazole formulation
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
EP1967184A4 (en) * 2005-12-28 2011-02-16 Takeda Pharmaceutical SOLID PREPARATION WITH CONTROLLED RELEASE
CA2634969A1 (en) * 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Controlled release solid preparation
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
KR101841662B1 (ko) * 2016-06-02 2018-03-23 동화약품주식회사 프로톤 펌프 저해제의 고체분산체 및 이를 포함하는 약제학적 조성물
EP4023216A4 (en) * 2019-10-17 2023-05-10 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION WITH PROTON PUMP INHIBITOR AND ANTACID
MX2022004464A (es) * 2019-10-17 2022-05-03 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de la bomba de protones y un antiacido.
WO2021150050A1 (ko) * 2020-01-23 2021-07-29 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제
CN111281855B (zh) * 2020-03-23 2021-09-24 乐普制药科技有限公司 一种雷贝拉唑肠溶片及其制备方法
KR102608889B1 (ko) * 2020-07-14 2023-12-04 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법
CN113384547B (zh) * 2021-06-25 2024-03-19 上海信谊万象药业股份有限公司 一种奥美拉唑铝碳酸镁复合片及其制备工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
EP1222922B1 (en) * 1999-10-20 2007-08-15 Eisai R&D Management Co., Ltd. Method for stabilizing benzimidazole compounds

Also Published As

Publication number Publication date
US20040248939A1 (en) 2004-12-09
EP1420763A1 (en) 2004-05-26
CA2448760A1 (en) 2003-03-06
PE20030436A1 (es) 2003-07-04
WO2003017980A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
AR036354A1 (es) Preparacion solida
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
RU2223964C2 (ru) Цефемовые производные, способ их получения, соединение, фармацевтическая композиция, способ лечения
ES2182535T3 (es) Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
ES2535311T3 (es) Formulaciones farmacéuticas de sales de galio
AR062224A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden.
AR045698A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
EP1306375A4 (en) SALTS OF BENZIMIDAZOLE DERIVATIVES AND THEIR USE
ES2195034T3 (es) Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
ATE40290T1 (de) Reinigungsmischung fuer zahnprothesen.
PA8591301A1 (es) Sales de aluminio de alta eficacia y baja irritacion y productos relacionados
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
ES2189502T3 (es) Metodo para la prevencion de citalopram.
GB0404574D0 (en) Amino acids
AR031305A1 (es) Agonistas del receptor alfa activado del proliferador de peroxisomas
ES2087097T3 (es) Derivados de acidos fenilcarboxilicos que contienen un heterociclo.
PT666731E (pt) Elixir dentifrico antibacteriano
AR092279A1 (es) Pirrol carboxamidas fluorometilo sustituidas
ES2059786T3 (es) Composicion blanqueante.
EA200601178A1 (ru) Морфолинилсодержащие бензимидазолы в качестве ингибиторов репликации респираторно-синцитиального вируса
BR112022012986A2 (pt) Soluções orais compreendendo sais de lisdexamfetamina
AR044864A1 (es) Composiciones orales antiplaca acuosas estables
HUP9901062A2 (hu) Vizes alapú szilikátkészítmények
AR043563A1 (es) Inhibidores de catepsina s

Legal Events

Date Code Title Description
FA Abandonment or withdrawal